Severe hemophilia A. In addition to bleeding after an injury, you may have frequent episodes of bleeding, often into the joints and muscles, without being able to figure out a specific cause.

A new study found that patients with hemophilia A could safely switch directly from emicizumab to Mim8 without a washout period, meaning they did not need to stop treatment before starting the new ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

Haemophilia A, also known as factor VIII deficiency, is a genetic disorder affecting blood clotting ability. This condition is one of the most common types of haemophilia and primarily affects ...

Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

Hemophilia is a hereditary genetic condition. Patients do not have the gene allowing blood to clot. There is no known permanent cure. New gene-therapy trial finds long-term cure ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of ...